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INTRODUCTION 
Nasal route has been demonstrated as being a possible 
alternative to the intravenous route for the systemic 
delivery of drugs. In addition to rapid absorption and 
avoidance of hepatic first-pass metabolism, the nasal route 
allows the preferential delivery of drug to the brain via the 
olfactory region, and is therefore a promising approach for 
the rapid-onset delivery of medications.1 
Therapy through intranasal administration has been an 
accepted form of treatment in the Ayurvedic system of 
Indian Medicine. In recent years many drugs have been 
shown to achieve better systemic bioavailability through 
nasal route than by oral administration.2 
In modern pharmaceutics, the nose had been considered 
primarily as a route for local drug delivery. Advances in 
biotechnology have made available a large number of 
protein and peptide drugs for the treatment of a variety of 
diseases. These drugs are unsuitable for oral administration 
because they are significantly degraded in the 
gastrointestinal tract or considerably metabolized by first 
pass effect in the liver. Even the parenteral route is 
inconvenient for long term therapy. Of the many alternate 
routes tried, intranasal drug delivery is found much 
promising for administration of these drugs.3 
The drugs showing poor bioavailabilities, typically in the 
order of 5–10% for large molecules. On the other hand, 
very good results were obtained with small organic 
molecules. 4 The causes of failure led to the conclusion that 
the short residence time of the formulation within the nasal 
cavity coupled to the low permeability. Consequently, the 
attention shifted to the evaluation of mucoadhesive 
polymers, some of which would even demonstrate 
additional permeation- enhancing capabilities.5,6 The 
encouraging results and the desire to overcome some new 
challenges stimulated the development of new generations 
of polymers based on pH or thermal responsiveness or 
modified existing polymers having improved bioadhesive 
or permeation-enhancing properties.7,8,9 Even though a 
number of challenges are still to be overcome, especially 
with respect to toxicity, the potential of nasal drug delivery 
(NDD), including the ability to target drugs cross the 
blood–brain barrier (BBB), are very high and continues to 
stimulate academic and industrial research groups so that 
we will keep witnessing increasing number of advanced 
nasal drug delivery products. 
1. NASAL ANATOMY AND PHYSIOLOGY  
The nasal cavity is divided into two halves by the nasal 
septum and extends posteriorly to the nasopharynx, while 
the most anterior part of the nasal cavity, the nasal 
vestibule, opens to the face through the nostril (Fig. 1). 
The atrium is an intermediate region between the vestibule 
and the respiratory region. The respiratory region, the 
nasal conchae or turbinates, which occupies the major part 
of the nasal cavity, possesses lateral walls dividing it into 3 
sections: the superior, middle and inferior nasal turbinates. 
The nasal vestibule has the smallest cross-sectional area in 
the respiratory tract (approximately 0.3 cm2 on each side) 
that extends from the entrance of nostril, which is guarded 
by vibrissae (hairs), to the anterior end of the inferior 
turbinate. The area from the anterior ends of the turbinate 
to the anterior portion of the nasopharynx constitutes the 
main nasal passages.10, 11 The epithelial cells in the nasal 
vestibule are stratified, squamous and keratinized with 
sebaceous glands (Fig.2). Due to its nature, the nasal 
vestibule is very resistant to dehydration and can withstand 
noxious environmental substances and limits permeation 
of substances. Microvilli are found on the columnar cell, 
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which increases the surface area available for absorption. 
The nasal mucosa is highly vasculature, superficial and 
deep layers of arterioles supply the lamina propria and 
between the venules and capillaries. Most of the area of the 
nasal cavity serves the function of cleaning the air we 
breathe before it reaches the lungs. It does this with the 
help of the respiratory mucosa, which lines the walls of the 
nasal cavity. Within this mucosa, small, hair-like cilia 
move in a wave-like motion, moving mucus to the back of 
the throat.10 
 
 
Figure 1: Structure of nasal cavity 
1.1 Nasal mucus secretion: 
The submucosal glands, which secrete the greater quantity 
of nasal mucus, comprise both mucus cells, secreting the 
mucus gels, and serous cells, producing a watery fluid.12 
Seromucus glands in the human nose have been estimated 
to be 100,000.13  Mucus is also released from the goblet 
cells as mucus granules, which swell in the nasal fluids to 
contribute to the mucus layer. Mucus secretion is a 
complex mixture of many substances and consists of about 
95% water, 2% mucin, 1% salts, 1% of other proteins such 
as albumin, immunoglobulins, lysozyme and lactoferrin, 
and <1% lipids.14 About 1.5–2 L of nasal mucus is 
produced daily. This mucus blanket, about 5 mm thick, 
consists of two layers, a lower sol layer and an upper gel 
layer. The viscosity of both layers affects ciliary beating 
and the efficiency of transporting the overlying mucus—
the mucociliary clearance (MCC). The nasal mucus 
performs a number of physiological functions. (1) It covers 
the mucosa, and physically and enzymatically protects it. 
(2) The mucus has water-holding capacity. (3) It exhibits 
surface electrical activity. (4) It permits efficient heat 
transfer. (5) It acts as adhesive and transports particulate 
matter towards the nasopharynx.
 
 
 
Figure 2: Nasal epithelium showing ciliated cell (A), non-ciliated cell (B), goblet cells (C), gel mucus layer (D), sol layer 
(E), basal cell (F) and basement membrane (G). 
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1.2. Mucociliary clearance: 
One of the functions of the upper respiratory tract is to 
prevent noxious substances (allergens, bacteria, viruses, 
toxins etc.) from reaching the lungs. When such materials 
adhere to, or dissolve in the mucus lining of the nasal 
cavity, they are transported towards the nasopharynx for 
eventual discharge into the GIT. Clearance of this mucus 
and the adsorbed/dissolved substances into the GIT is 
called the MCC. It consists of a coordinated interaction 
between the overlying mucus layer and the methachronal 
wavelike movement of the underlying cilia. Cilia are hair-
like protrusions on the epithelial cell surface. There are 
approximately 300 cilia per cell, each cilia is 5–10 mm 
long and 0.1–0.3 mm wide and beats at a frequency of 
about 20 Hz. 
The MCC can be influenced by environmental and 
pathological conditions. Factors that can increase ciliary 
beat frequency (CBF) and mucus production, or decrease 
mucus viscosity will all lead to increase in MCC. 
Environmental conditions like temperature (below or 
above 230 C), inhalation of sulfur dioxide and cigarette 
smoke all decrease MCC.14,15 Such pathological conditions 
like Sjorgens syndrome, asthma, nasal polyposis, defective 
septum, rhinitis, allergy, common cold and sinusitis alter 
MCC due to their effects on CBF or mucus rheology. Two 
mechanisms have been suggested to be involved in 
increased mucus secretion irrespective of the causative 
factors. First, mast cell-derived mediators released in the 
nasal mucosa may induce secretion of nasal mucus 
glycoproteins. Second, neurohormones released may cause 
an increase in nasal blood flow and increase in 
transudation of fluid and plasma proteins.16 All the 
pathological and environmental conditions above will 
ultimately alter nasal drug delivery and the performance of 
nasal mucoadhesive formulations, and should be taken into 
account during product development.  
1.3. Nasal mucus & mucus-drug interaction: 
Nasal mucus is produced by the nasal mucosa, and mucal 
tissues lining the airways (trachea, bronchus, bronchioles) 
is produced by specialized airway epithelial cells (goblet 
cells) and submucosal glands. Small particles such as dust, 
particulate pollutants, and allergens as well as infectious 
agents such as bacteria are caught in the viscous nasal or 
airway mucus and prevented from entering the system. 
This event along with the continual movement of the 
respiratory mucus layer toward the oropharynx, helps 
prevent foreign objects from entering the lungs during 
breathing. Additionally, mucus aids in moisturizing the 
inhaled air and prevents tissues such as the nasal and 
airway epithelia from drying out.17 Nasal and airway 
mucus is produced constitutively, with most of it 
swallowed unconsciously, even when it is dried.18 
Table 1: Different sections of nasal cavity and their relative permeability 
S. No.           Region                                Permeability 
1.  Nasal Vestibule Least permeable because of presence of keratinized cells 
2.  Atrium Less permeable as it has small surface area and stratified cells are present 
3.  Respiratory Region Most permeable region because of large surface area and rich vasculature 
4.  Olfactory  Region Direct access to cerebrospinal fluid 
5.  Nasopharynx Receives nasal cavity drainage 
 
Increased mucus production in the respiratory tract is a 
symptom of many common illnesses, such as the common 
cold and influenza. Similarly, hypersecretion of mucus can 
occur in inflammatory respiratory diseases such as 
respiratory allergies, asthma, and chronic bronchitis.17 The 
presence of mucus in the nose and throat is normal, but 
increased quantities can impede comfortable breathing and 
must be cleared by blowing the nose or expectorating 
phlegm from the throat. Tears are also a component of 
nasal mucus. 
Mucin is the major component of mucus. This compound, 
primarily responsible for the viscoelastic properties of the 
mucus, is found in 2 forms: soluble secretory mucin and 
membrane-bound mucin.16,19 Mucins are heterogenous 
macromolecules composed of approximately 10–30% by 
weight of peptide core linked to oligosaccharide chains 
that make up 70– 80% of the total weight.20 
It is an important consideration to understand how the 
mucus and drugs interact with each other, and even more 
importantly how such interactions could influence drug 
absorption and activity. The drug’s molecular size, the 
mucus mesh size and the interaction between the mucus 
gel and the drug influence the diffusion of drugs through 
the mucus. Like in all cases of diffusion, small and neutral 
molecules diffuse faster and to a greater extent through a 
charged matrix compared to charged and large molecules. 
It should be highlighted that some large or charged 
molecules have been observed to diffuse readily through 
the mucus.21 Additionally, particulate materials, e.g., 
microspheres and liposomes bearing drugs, have been 
observed to diffuse through the mucus and reach the 
epithelium intact. 
Studies on particulate transport through the mucus all 
demonstrated that diffusion is size dependent and 
decreases quickly with increasing size.22 
1.4.  Polymer–mucus interaction: 
Several theories have been put forward to explain the 
mechanism of polymer–mucus interactions that lead to 
mucoadhesion. The sequential events that occur during 
bioadhesion include an intimate contact between the 
bioadhesive polymer and the biological tissue due to 
proper wetting of the bioadhesive surface and swelling of 
the bioadhesive polymer, this leads to the penetration of 
the bioadhesive into the tissue crevices, interpenetration 
between the mucoadhesive polymer chains and those of 
the mucus. Subsequently low chemical bonds can become 
operative.23,24 Hydration of the polymer plays a very 
important role in bioadhesion. There is a critical degree of 
hydration required for optimum bioadhesion. If there is 
incomplete hydration, the active adhesion sites are not 
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completely liberated and available for interaction. On the 
other hand, an excessive amount of water weakens the 
adhesive bond as a result of an overextension of the 
hydrogen bonds. During hydration, there is a dissociation 
of hydrogen bonds of the polymer chains. The polymer–
water interaction becomes greater than the polymer–
polymer interaction, thereby making the polymer chains 
available for mucus penetration.25 
The adsorption theory of bioadhesion proposes that 
adhesion of a polymer to a biological tissue results from: 
(1) primary chemical bonds that are somewhat permanent 
and therefore undesirable in bioadhesion, (2) Vander 
Waals, hydrogen, hydrophobic and electrostatic forces, 
which form secondary chemical bonds.26 The electronic 
theory proposes the existence of an electrical charge 
double layer at the interface between the adhesive and 
biological tissue as a result of the difference in their 
electronic structure.27 
1.5. Factors that influence mucoadhesion: 
The factors that influence mucoadhesiveness of a polymer 
includes, physiological factors polymer related factors and 
environmental factors. 
1.5.1. Physiological-related factors: 
MCC, mucus turnover and disease states are physiological 
factors which influence nasal mucoadhesion. 
Mucoadhesion can slow down MCC, but with time mucus 
production reduces the mucoadhesion bond strength, 
allowing a recovery of MCC to normal clearance rates, 
thereby removing the mucoadhesive. Disease conditions 
mentioned earlier can affect mucoadhesion due to their 
influence on either mucus production or ciliary beating. 
Thus a good understanding of the nature of mucus in these 
diseases is imperative in designing a good novel drug 
delivery (NDD) system. An abnormal mucus layer could 
present an unanticipated barrier to drug transport through 
the mucosa. Mucoadhesive capabilities of polymers should 
be studied during product development under such disease 
conditions considered relevant. 
1.5.2. Polymer-related factors: 
The polymer molecular mass will influence its bioadhesion 
characteristics. There is a critical polymer molecular mass 
and cross-linking density below or above which there is 
reduced adhesive power, and this varies with the type of 
polymer.28,29 Mucoadhesion requires an adequate free 
chain length for interpenetration to occur. Reducing the 
free chain length by extensive cross-linking therefore 
reduces mucoadhesion.28,30 An optimum polymer 
concentration is required at the polymer–mucus interface 
for bioadhesion, beyond which few polymer chains will be 
available for polymer–mucus interpenetration. The 
polymer concentration that is required for optimum 
bioadhesion is different between gels and solid 
bioadhesives. In the liquid state, an optimum concentration 
exists for each polymer beyond that reduced adhesion 
results because fewer polymer chains will be available for 
interpenetration with the mucus. On the other hand, with 
solid dosage forms such as buccal tablets, increased 
polymer concentration leads to increased mucoadhesive 
power.24,31,32 
1.5.3. Environmental factors: 
Polymer hydration and swelling are required for initiation 
of mucoadhesion but excessive hydration with inordinate 
swelling of the polymer reduces its adhesive strength. The 
swelling/hydration rate should not be too rapid in order to 
prolong the adhesion time. 
On the other hand, inordinate swelling is eventually 
required to reduce polymer adhesiveness and to allow it to 
detach from the biological tissue. Some polymers owe 
their mucoadhesiveness to such forces as hydrogen 
bonding, van der Waals, hydrophobic and electrostatic 
forces. The strength of these forces is influenced by the 
environmental pH. 
Consequently, for such polymers, environmental pH is a 
very important determinant of mucoadhesive strength.  
2. NASAL DOSAGE FORM AND DELIVERY 
SYSTEM  
The final dosage form used for nasal drug delivery is 
chosen after consideration of a wide range of factors, 
covering patient convenience, efficiency of drug delivery 
and formulation reasons. Nasal sprays, squeeze bottles, 
and liquid droppers are some of the more common delivery 
methods that can be seen as nasal dosage forms. There are 
three main ways of depositing inhaled particles or the nasal 
lining: impaction, sedimentation and diffusion. Impaction 
occurs when there is a change in direction of the airflow - 
as happens when inspired air passes through the nasal 
valve – and the inertia of large or fast-moving particles 
carries them in their original direction. Sedimentation 
happens when the moving slowly and the particles settle 
slowly under the force of gravity. The final method of 
deposition diffusion occurs by Brownian motion and is 
thus limited to very small particles (< 0.5 mm). Nasal 
dosage forms will usually contain the drug in a liquid or 
powder formulations delivered by a pressurized or pump 
system.  
Table 2: Summary of some nasal drug delivery studies where mucoadhesive polymers were employed 
    S.No.       Drug                                         Mucoadhesive polymer                       Dosage form        Animal species 
1.  Gentamicin Chitosan Powder Rabbit 
2.  Ciprofloxacin  HPMC Gel Rabbit 
3.  Insulin Chitosan glutamate Liquid Sheep 
4.  Insulin  Maltodextrin DE 22 Powder Rabbits 
5.  Apomorphine  Carbopol 971P Powder Rabbits 
6.  Pentazocine  Chitosan microspheres Powders Rabbits 
7.  Dopamine  Hydroxypropyl cellulose Solution Dogs 
8.  Metoprolol tartrate  Alginate microspheres Liquid Rabbits 
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Liquid formulations used for nasal drug delivery are 
usually aqueous solutions of the drug and thus have the 
general benefits and drawbacks of pharmaceutical 
solutions. They are relatively simple to develop and 
manufacture compared to solid dosage forms but often 
have a lower microbiological and chemical stability, 
requiring the use of various preservatives. Squeezed 
bottles are often used for nasal decongestants and work by 
spraying a partially atomized jet of liquid into the nasal 
cavity. They give a better absorption of drug by directing 
the formulation into the anterior part of the cavity and 
covering a large part of the nasal mucosa. Metered-dose 
pump systems offer greater control over dosing than any of 
the previous systems discussed above. They can deliver 
solutions, suspensions or emulsions, with a predetermined 
volume between 25 and 200 mL, thus offering deposition 
over a large area. Particle size and dose volume are two, 
important factors for controlling delivery from metered-
dose systems. Nasal sprays are available as squeeze 
bottles, which would not be expected to give reproducible 
dosing. They are also available as metered-dose devices, 
which would be expected to give more reproducible 
dosing, as a mechanical actuation delivers a pre-
determined volume to the patient. Nasal drops rely upon 
the instillation of one or more drops of drug solution, 
either from a dropper with a flexible (rubber) teat, or 
directly from a “squeezable” plastic container into the 
nasal cavity.  
Many conventional drugs have been investigated for 
systematic delivery via the nasal cavity and these are of 
relatively low molecular weight (in most cases less than 
500 Da). However, peptides and proteins generally have a 
molecular weight in excess of 1,000 Da and are therefore 
unlikely to be absorbed across the nasal mucosa in any 
appreciable amounts without pharmaceutical intervention. 
New technologies in nasal delivery are primarily 
concerned with strategies to increase drug absorption. 
Drug absorption can be increased by one of the techniques 
like use of surfactant increasing the permeability of nasal 
epithelium, altering the mucus layer, altering the tight 
junctions, reverse micelle formation, erosion of mucosal 
layer, increasing contact time at the site of absorption, 
modifying the site of deposition, use of bioadhesives, 
reducing rate of mucociliary clearance and inhibition of 
enzymatic degradation.33  
Apart from liquid, powder and gels some novel drug 
delivery system are being used to deliver drug via nasal 
route. This drug delivery system includes microspheres34, 
liposomes and nanoparticles.35 Microsphere technology is 
one of the specialized systems becoming popular for 
designing nasal products, as it may provide prolonged 
contact with the nasal mucosa and thus enhances 
absorption and bioavailability. In the presence of 
microspheres, the nasal mucosa is dehydrated due to 
moisture uptake by the microspheres. This result in 
reversible shrinkage of the cells, providing a temporary 
physical separation of the tight (intercellular) junctions that 
increases the absorption of the drugs.36 Particularly 
important for the nasal drug absorption is the respiratory 
region, which contains three nasal turbinates and the 
deposition of the particles in this region will depend on 
their size. Classically, larger particles including droplets 
(>10 µm), are deposited in the nasal cavity after inhalation, 
the larger the particles, the more anterior the deposition. 
For smaller particles the site of deposition depends on the 
velocity at which the particles are inhaled and the 
turbulence in the air flow, however the particles of size 
smaller than 1 µm are not normally deposited in the nasal 
cavity but travel down to the trachea to reach the lung. The 
rationale behind the use of a microsphere system is that, 
the application of bioadhesive microspheres (in the powder 
form) with good bioadhesive properties would permit such 
microspheres to swell in contact with nasal mucosa to form 
a gel and control the rate of clearance from the nasal 
cavity, thereby giving poorly absorbed drugs a longer time 
to be available at the absorptive surface. Microspheres 
have been reported to be present up to 3-5 h in the nasal 
cavity depending upon the bioadhesive material used for 
formulation. The ideal microsphere particle size 
requirement for nasal delivery should range from 10 to 50 
µm as smaller particles than this will enter the lungs.  
Nanoparticles are solid colloidal drug delivery system, 
submicron in size from 1-1000 μm. The drug molecules 
are either encapsulated or adsorbed on the nanoparticles. 
They possess better reproducibility and stability profile 
than liposomes. They offer non-invasive route of 
administration via nasal route also. Nanoparticles have 
been used to deliver drugs as well as vaccines through 
nasal route.35 
3. APPLICATION OF NASOADHESIVE DRUG 
DELIVERY IN PHARMACEUTICALS  
3.1. Antibiotics: 
 Recently a few studies have examined the potential of the 
nasal route for systemic delivery of antibiotics using 
mucoadhesive polymers. In a preliminary study, Lim et al. 
37 prepared and evaluated mucoadhesive microspheres of 
hyaluronic acid and chitosan for nasal delivery of 
gentamicin and other drugs. The study showed that 
hyaluronic acid and hyaluronic acid/chitosan microspheres 
could adhere to the nasal mucus. Subsequently, the authors 
showed that hyaluronic acid and chitosan may be 
employed for nasal administration of antibiotics to obtain a 
high bioavailability and prolonged release.
38
  Successful 
nasal delivery of other antibiotics such as vancomycin and 
tobramycin with chitosan has been reported as well.39 It 
was shown that the presence of chitosan salts slow down 
the release of vancomycin hydrochloride at pH 5.5 and pH 
7.4. 
 Although it is very interesting to deliver antibiotics 
through the nasal route, the use of mucoadhesives raises 
important safety concerns due to the prolonged drug–
polymer residence time in the nasal mucosa, which may 
lead to superinfection in the respiratory tract. The 
increased contact time may upset the nasal normal 
microbial flora when broadspectrum antibiotics are used. 
This may lead to superinfection as documented for the 
gastrointestinal mucosa. This should be considered when 
selecting antibiotics to be delivered nasally using 
mucoadhesives. 
3.2. Macromolecules: 
3.2.1. Vaccines and DNA: 
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Vaccination through nasal cavity  is another interesting 
tool for pathogenic infections such as influenza, pertussis, 
meningitis, measles, etc.. The route of administration is 
easy, cheap and can be administered to a large population. 
It eliminates the use of needles and as such risk of 
infections (especially in poor countries) with hepatitis B, 
HIV, etc. There is a relatively large surface area through 
which uptake of the antigenic material can take place. 
Mucosal immunization may be safer and more successful 
in young children in the presence 
of marternal antibodies as demonstrated by the high 
effectiveness of the live polio vaccine when given at birth. 
A recent review article by Lemoine et al.40 summarized 
vaccination using nasally administered microparticles. In 
the studies cited, various levels of immune responses were 
induced. Vila et al.41 studied nasal immunization with 
tetanus toxoid following encapsulation and administration 
in the forms of PEG-coated polylactic acid nanospheres, 
chitosan-coated polylactic– glycolic acid nanospheres and 
chitosan nanospheres. They observed that PEG-coated 
nanospheres induced higher levels of tetanus toxoid in the 
blood compared to chitosan-coated nanospheres. On the 
other hand, very high IgG titers were obtained 6 months 
post administration of chitosan nanospheres.  
3.2.2. Proteins: 
Low absorption of the compounds such as high molecular 
weight proteins occurs due to, rapid mucociliary clearance 
and enzymatic degradation. Some mucoadhesive polymers 
have been suggested to extend residence time and improve 
uptake of large molecules across the nasal mucosa.42 Non-
protein high molecular weight compounds (e.g., mannitol, 
cyanocobalamin) have been used as surrogates in search of 
mucoadhesives for nasal administration of proteins.43 Such 
studies have yielded useful information regarding nasal 
protein delivery with mucoadhesives. Garcia et al.44 
showed that incorporation of cyanocobalamin into 
microcrystalline cellulose, dextran microspheres, and 
crospovidone resulted in significant improvement in 
bioavailability of cyanocobalamin relative to simple nasal 
solutions in rabbits. In another study, Hamman et al.
45
  
examined the effect of the degree of quaternization of 
mucoadhesive N-trimethyl chitosan chloride (TMC) on 
nasal absorption enhancement of [14C]- mannitol in rats. 
3.3. Small organic molecules: 
Due to the rapid therapeutic action that can be achieved, 
medications used in emergency medical situations make 
ideal candidates for nasal drug delivery. One such drug, 
apomorphine is the drug of choice for treatment of on/off-
syndrome in patients suffering from Parkinson’s disease. 
Aqueous solution of the compound is reasonably well 
absorbed following nasal administration with a relative 
bioavailability of 45%.46 Apart from increasing the 
mucosal contact time for the drug, mucoadhesive powder 
formulations had the added advantage of limiting oxidation 
due to aqueous environment. Although the nasal 
mucoadhesive formulations prepared with Carbopol 974P 
had better pharmacokinetic profiles than nasal solutions, 
the study showed that physicochemical characteristics of a 
drug molecule and its release from the polymer matrix 
could affect the rate and extent of drug absorption. 
Therefore, incorporation of a rapid release excipient (e.g., 
lactose) may be of relevance as demonstrated for 
apomorphine formulated with Carbopol 974P.47 
Apomorphine absorption was fastest following intranasal 
administration of immediate release forms prepared with 
lactose compared to subcutaneous injections.  
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